Ioannidou Sofia 4
4 · LogicBio Therapeutics, Inc. · Filed Oct 25, 2018
Insider Transaction Report
Form 4
Ioannidou Sofia
Director
Transactions
- Purchase
Common Stock
2018-10-23$10.00/sh+420,000$4,200,000→ 1,787,413 total(indirect: See Footnote) - Conversion
Series B Convertible Preferred Stock
2018-10-23−2,611,665→ 0 total(indirect: See Footnote)→ Common Stock (1,367,413 underlying) - Conversion
Common Stock
2018-10-23+1,367,413→ 1,367,413 total(indirect: See Footnote)
Footnotes (2)
- [F1]Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock.
- [F2]The Reporting Person is a director of Andera Partners, the company managing BioDiscovery 5. BioDiscovery 5 is the direct beneficial owner of these securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.